Remimazolam has completed its main clinical development studies for procedural sedation in adults. Procedural sedation is a technique of administering sedatives or dissociative agents, with or without analgesics, to induce a mental state that allows the patient to tolerate unpleasant diagnostic and therapeutic procedures such as colonoscopy while maintaining cardiorespiratory function. This enables medical procedures to be carried out with the patient benefit of markedly reduced discomfort and no major added risk.
Remimazolam is an ultra-short-acting intravenous benzodiazepine sedative/anaesthetic that in the human body is rapidly transformed (metabolized) to an inactive metabolite. Remimazolam is structurally similar to the commonly used sleep-inducing drug midazolam, but it incorporates the pharmacokinetic properties of remifentanil to make the offset of sedation faster and more predictable. If licensed, remimazolam will offer an additional therapy option for procedural sedation in adults during a diagnostic and/or therapeutic procedures.
Abilify MyCite is a drug-device combination comprising aripiprazole embedded with an Ingestible Event Marker (IEM) sensor. The aripiprazole attaches in the brain to receptors which help normalise the activity of the brain. The drug is packaged within an innovative system which helps patients (and healthcare workers) monitor when the medication is taken through integration with a sensor patch and app. Abilify MyCite is different to other ways of monitoring whether medication has been taken because it gives results of the actual medication taken, without need for blood or urine samples, as opposed to an estimate and if licensed, will offer an additional treatment option for patients with BP1 and SCH.